
Curious Conversation with My AI Pal: Unraveling the Mysteries of Proactive Investors’ Top Headline ‘AIM-Listed Firm Reports Strong H1 Results’
hVIVO PLC and Inhalon Biopharma Join Forces to Combat Respiratory Syncytial Virus In an exciting turn of events, hVIVO PLC (AIM:HVO), a leading clinical research organization specializing in respiratory infections, has recently announced a partnership with Inhalon Biopharma. The collaboration aims to evaluate Inhalon’s antiviral treatment, IN-002, against the notoriously tenacious Respiratory Syncytial Virus (RSV)….